Q-omics provides the consensus-scored ZNF776 profile across patient tissues and cancer cell-line models. ZNF776 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF776 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, ZNF776 RNA expression shows 22,073 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where ZNF776 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF776 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF776 survival associations across molecular data types. ZNF776 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF776 RNA expression–survival associations across cancer types. High ZNF776 expression shows unfavorable associations in CESC, LGG and HNSC, but favorable associations in KIRC, SCLC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF776 RNA expression.
This table summarizes ZNF776 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF776. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF776 shows lower tumor expression in THCA and higher tumor expression in BLCA, BRCA, HNSC, CHOL and STAD. The BLCA box plot shows higher ZNF776 RNA expression in tumor versus normal tissue (log2 FC = +0.745, t-test p < 0.001).
This table shows molecular features associated with ZNF776 in patient tissues and cancer cell lines. In patient samples, ZNF776 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF776 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
